基于机架的5次大分割选择性淋巴结照射在高危前列腺癌中的疗效:SABR推量与MR剂量描绘HDR近距离推量的两项前瞻性研究比较
两项前瞻性2期研究比较了5次盆腔放疗联合SABR推量或MR引导HDR近距离治疗推量(均联合6-18个月ADT)在高危前列腺癌中的疗效、毒性和生活质量。两组急性和晚期胃肠及泌尿生殖毒性无显著差异,生活质量无显著差异或仅有极小临床重要变化。
要点
- 5次盆腔放疗联合SABR推量或HDR-BT推量,毒性及生活质量无显著差异。
- SABR组5年生化失败率0%,HDR-BT组18.2%,疗效倾向SABR但需考虑序贯2期研究比较的偏倚。
- HDR-BT组3%患者出现3级晚期泌尿生殖毒性。
核心结论
- 在5次盆腔放疗和ADT背景下,SABR推量与HDR-BT推量在毒性和生活质量方面无显著差异。
- 疗效方面SABR推量组更优,但需考虑两项序贯2期研究比较的局限性和偏倚。
研究设计与样本
- SPARE研究(研究2):31例患者接受前列腺HDR-BT(15 Gy×1)和MRI结节≤22.5 Gy,随后盆腔25 Gy分5次每周照射。
- 所有患者接受6至18个月ADT。
主要发现
- 研究1中7%为中危不利风险,93%为高危(NCCN标准);研究2中3%为中危有利风险,47%为中危不利风险,50%为高危。
- 中位随访时间分别为72个月和62个月。
- 研究2中6例出现生化失败,且全部6例发生转移。
- 急性和晚期胃肠及泌尿生殖毒性最差等级无显著差异;研究2中3%患者出现3级晚期泌尿生殖毒性。
关键数值与推荐
- 3级晚期泌尿生殖毒性:HDR-BT推量组3%。
临床怎么用
- 对于接受5次盆腔放疗和ADT的高危前列腺癌患者,SABR推量可作为HDR-BT推量的替代选择,毒性和生活质量相似。
- SABR推量可能改善生化控制,但需谨慎解读,因比较存在偏倚。
局限性
- 比较两项序贯2期研究存在局限性和偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Guidelines from the American Society of Clinical Oncology and Cancer Care Ontario recommend brachytherapy boost for patients with intermediate-risk or high-risk prostate cancer. SABR is an emerging technique for prostate cancer, but its use in high-risk disease is limited. Efficacy, toxic effects, and quality of life (QoL) were compared in patients treated on 2 prospective protocols that used SABR boost or magnetic resonance-guided high-dose-rate brachytherapy (HDR-BT) boost with 6 to 18 months of androgen deprivation therapy (ADT). METHODS AND MATERIALS: In SATURN study (study 1), patients received 40 Gy to the prostate and 25 Gy to the pelvis in 5 weekly fractions. In SPARE (study 2), patients received HDR-BT (15 Gy × 1) to the prostate and ≤22.5 Gy to the magnetic resonance imaging nodule, followed by 25 Gy in 5 weekly fractions to the pelvis. All patients received between 6 and 18 months of ADT. RESULTS: Thirty patients (7% unfavorable intermediate risk and 93% high risk, per National Comprehensive Cancer Network [NCCN] criteria) completed study 1, and 31 patients (3% favorable intermediate risk, 47% unfavorable intermediate risk, and 50% high risk) completed treatment as per study 2. The median follow-up times were 72 and 62 months, respectively. In study 2, 6 patients had biochemical failure, and all 6 developed metastatic disease. Actuarial 5-year biochemical failure was 0% for study 1 and 18.2% for study 2 (P = .005). There was no significant difference in the worst acute or late gastrointestinal or genitourinary toxicity. Grade 3 late genitourinary toxicity was noted in 3% of the patients in study 2 (HDR-BT boost). There was either no significant difference or minimal clinically important change in QoL. CONCLUSIONS: In the context of 5-fraction pelvic radiation therapy and ADT, there did not appear to be a significant difference in toxicity or QoL between SABR and HDR-BT boost. Although efficacy favored the SABR boost cohort, this should be viewed in the context of limitations and biases associated with comparing 2 sequential phase 2 studies.
引用
- Musunuru HB, Cheung P, Vesprini D, et al. Gantry-Based 5-Fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes From 2 Prospective Studies Comparing SABR Boost With MR Dose-Painted HDR Brachytherapy Boost. Int J Radiat Oncol Biol Phys. 2021. PMID: 34637882. doi:10.1016/j.ijrobp.2021.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。